Possible Acute uveitis with vitreous humor inflammation; This spontaneous case was reported by a patient and describes the occurrence of UVEITIS (Possible Acute uveitis with vitreous humor inflammation) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037k20a and 012m20a) for COVID-19 prophylaxis.     No Medical History information was reported.   On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, the patient experienced UVEITIS (Possible Acute uveitis with vitreous humor inflammation) (seriousness criterion medically significant). At the time of the report, UVEITIS (Possible Acute uveitis with vitreous humor inflammation) had not resolved.            No concomitant medication were reported.  Patient reported that following vaccination 1 week after the 2nd dose, 5 weeks after the 1st dose he experienced bilateral eye inflammation and pain, photophobia, redness, eye floaters.  Patient went to eye doctor about a month after it began which resulted in vision therapy on Sep 2021. Patient symptoms never resolved. Patient has not experienced a similar event in the past. Pain was resolved, the floaters were still present. Patient stated symptoms were the same or slightly better.  Patient received over the counter NSAIDS for the pain.  Patient did not have any allergies to (medications, food and other products). Patient never tested positive for COVID or diagnosed with same. Patient historical condition was not related to mentioned AE at the time of vaccination. Patient had not taken other vaccines within 1 month prior to Moderna COVID-19 vaccine.  Company Comment: This is a spontaneous case concerning a 38-year-old male patient with no reported medical history, who experienced the unexpected, serious (medically significant) event of Uveitis, 1 week after receiving the second dose of mRNA-1273 vaccine. The patient reported to have bilateral eye inflammation with pain, photophobia, redness and eye floaters and went to an eye doctor after one month from onset and was diagnosed with possible acute uveitis with vitreous humor inflammation. The patient received nonsteroidal anti-inflammatory drugs for pain and underwent vision therapy 7 months later. The event had not resolved at the time of the report. It should be noted that the patient received the two doses of mRNA-1273 vaccine on approximately 4 weeks interval. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 38-year-old male patient with no reported medical history, who experienced the unexpected, serious (medically significant) event of Uveitis, 1 week after receiving the second dose of mRNA-1273 vaccine. The patient reported to have bilateral eye inflammation with pain, photophobia, redness and eye floaters and went to an eye doctor after one month from onset and was diagnosed with possible acute uveitis with vitreous humor inflammation. The patient received nonsteroidal anti-inflammatory drugs for pain and underwent vision therapy 7 months later. The event had not resolved at the time of the report. It should be noted that the patient received the two doses of mRNA-1273 vaccine on approximately 4 weeks interval. The benefit-risk relationship of mRNA-1273 is not affected by this report.